CN1307881C - 含银杀菌剂H4Ag2O6的新用途及其制备的药物 - Google Patents
含银杀菌剂H4Ag2O6的新用途及其制备的药物 Download PDFInfo
- Publication number
- CN1307881C CN1307881C CNB2004100622951A CN200410062295A CN1307881C CN 1307881 C CN1307881 C CN 1307881C CN B2004100622951 A CNB2004100622951 A CN B2004100622951A CN 200410062295 A CN200410062295 A CN 200410062295A CN 1307881 C CN1307881 C CN 1307881C
- Authority
- CN
- China
- Prior art keywords
- tinea
- containing silver
- bactericide
- medicine
- silver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000004332 silver Substances 0.000 title claims abstract description 41
- 229910052709 silver Inorganic materials 0.000 title claims abstract description 41
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 38
- 239000003899 bactericide agent Substances 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title claims abstract description 31
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 37
- 208000031888 Mycoses Diseases 0.000 claims abstract description 11
- 208000007313 Reproductive Tract Infections Diseases 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 24
- 208000002474 Tinea Diseases 0.000 abstract description 9
- -1 silver ions Chemical class 0.000 abstract description 6
- 241000130764 Tinea Species 0.000 abstract description 5
- 208000007163 Dermatomycoses Diseases 0.000 abstract description 4
- 206010067197 Tinea manuum Diseases 0.000 abstract description 4
- 208000006374 Uterine Cervicitis Diseases 0.000 abstract description 4
- 206010000496 acne Diseases 0.000 abstract description 4
- 206010008323 cervicitis Diseases 0.000 abstract description 4
- 201000003929 dermatomycosis Diseases 0.000 abstract description 4
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 3
- 206010017533 Fungal infection Diseases 0.000 abstract description 3
- 206010043866 Tinea capitis Diseases 0.000 abstract description 3
- 208000004926 Bacterial Vaginosis Diseases 0.000 abstract description 2
- 206010018612 Gonorrhoea Diseases 0.000 abstract description 2
- 241000204031 Mycoplasma Species 0.000 abstract description 2
- 208000010195 Onychomycosis Diseases 0.000 abstract description 2
- 201000010618 Tinea cruris Diseases 0.000 abstract description 2
- 208000007074 Trichomonas Vaginitis Diseases 0.000 abstract description 2
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 abstract description 2
- 230000003628 erosive effect Effects 0.000 abstract description 2
- 201000005882 tinea unguium Diseases 0.000 abstract description 2
- 206010005913 Body tinea Diseases 0.000 abstract 1
- 208000007190 Chlamydia Infections Diseases 0.000 abstract 1
- 206010012504 Dermatophytosis Diseases 0.000 abstract 1
- 241001460074 Microsporum distortum Species 0.000 abstract 1
- 206010028470 Mycoplasma infections Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 abstract 1
- 201000009642 tinea barbae Diseases 0.000 abstract 1
- 201000003875 tinea corporis Diseases 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 206010046914 Vaginal infection Diseases 0.000 description 4
- 201000008100 Vaginitis Diseases 0.000 description 4
- 229940095731 candida albicans Drugs 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000019477 peppermint oil Nutrition 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 229910001923 silver oxide Inorganic materials 0.000 description 3
- 229910000108 silver(I,III) oxide Inorganic materials 0.000 description 3
- 201000004647 tinea pedis Diseases 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 241000905957 Channa melasoma Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000223229 Trichophyton rubrum Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- OQXSRALAOPBHPM-UHFFFAOYSA-N 2-hydroxypropanoic acid;silver Chemical compound [Ag].CC(O)C(O)=O OQXSRALAOPBHPM-UHFFFAOYSA-N 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010008326 Cervicitis gonococcal Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- 241000893980 Microsporum canis Species 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241001480048 Trichophyton tonsurans Species 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 241001480050 Trichophyton violaceum Species 0.000 description 1
- 206010067409 Trichophytosis Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 201000010439 acute gonococcal cervicitis Diseases 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229940048368 flamazine Drugs 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000028320 gonococcal cervicitis Diseases 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000008921 jie er yin Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 229940071536 silver acetate Drugs 0.000 description 1
- 229940071575 silver citrate Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000009189 tinea favosa Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QUTYHQJYVDNJJA-UHFFFAOYSA-K trisilver;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ag+].[Ag+].[Ag+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QUTYHQJYVDNJJA-UHFFFAOYSA-K 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供了一种以含银杀菌剂H4Ag2O6为有效成分的防治妇女生殖道感染和皮肤浅部真菌感染的药物，其凝胶剂药物组方是，浓度3000ppm的H4Ag2O6溶液100ml，聚乙二醇55.690g，卡伯母42.690g，羟基苯甲酸甲酯0.5，蒸馏水加至组方总量为1000g。本发明以含银杀菌剂H4Ag2O6为有效成分制备的药物，可用于治疗妇科生殖道感染，包括细菌性阴道炎、念珠菌性阴道炎、滴虫性阴道炎、混合性阴道炎、支原体衣原体感染、淋球菌感染、宫颈炎和宫颈糜烂等；还可用于治疗治疗皮肤浅部真菌感染，包括痤疮、粉刺、发癣、须癣、体癣、股癣、手癣、足癣或脚气、黄癣、甲癣、牛皮癣和迭癣。
Description
技术领域
本发明涉及的是医用杀菌剂，特别是关于含银杀菌剂H4Ag2O6的新用途及其制备的药物。
背景技术
妇科生殖道感染疾病是妇女的常见病和多发病，临床上大多用抗生素及一些中药产品来治疗。但是，抗生素的大量使用，会导致抗药性致病菌的迅速蔓延，加上女性本身的生理特点，使临床对这类疾病的治疗力不从心，因此，目前人们正在寻找更好的解决方案。
皮肤浅部真菌病，是一种由寄生于角蛋白组织的致病真菌所引起的皮肤疾病，其流行颇广，遍布在世界各地，在我国也是常见多发病。据上海有关医院报告，该类皮肤疾病的发病率，占皮肤科门诊患者总数的第二位或第三位，有的甚至居首位。目前对于这种疾病，主要应用抗真菌的化学药品全身或局部给药治疗，但是，存在着真菌的耐药性和治愈后易复发等问题。
银具有杀菌性能，并且不产生耐药性，其抗菌机理是：1、银与致病菌代谢酶中的巯基结合，使酶失活，致使致病菌不能代谢而死亡；2、银和细菌细胞壁上暴露的肽聚糖反应，形成可逆性复合物，使其不能把氧转运进细胞，阻止病菌活动，导致其死亡；3、银离子和致病菌中的DNA碱基结合，银离子彼此形成交叉链接，导致DNA结构变性，抑制其复制，使致病菌失活。
银在金属状态下本身不能杀菌，只有银离子状态才具有抗菌性能。在银的化合物中，硝酸银溶于水，溶液中银为离子状态，但是，溶液中存在的大量硝酸根限制了银离子的应用。还有一些银盐，如：蛋白银、乙酸银、乳酸银、柠檬酸银和磺胺嘧啶银等，被应用到伤口敷料中。现有技术中未见有关于高浓度银离子溶液应用于医疗方面的报道。
本发明申请人持有专利权的中国专利ZL97108681.8，公开了一种含银杀菌剂的制备方法，具体步骤如下：(1)取银的氧化物(包括氧化银或过氧化银)，加入蒸馏水；(2)搅拌后，加入浓硫酸，调整pH值；(3)澄清后倒出澄清液，得到沉淀物；(4)向沉淀物中加入过氧化氢，得到含银杀菌剂。该含银杀菌剂为含银水合物，分子式表示为H4Ag2O6，该方法为含银杀菌剂H4Ag2O6在制药方面的应用提供了必要的条件。
发明内容
本发明的目的是提供含银杀菌剂H4Ag2O6的一种新用途及其制备的药物。
本发明发明人的研究表明，含银杀菌剂H4Ag2O6具有防治妇女生殖道感染和皮肤浅部真菌感染的作用，可用于制备防治妇女生殖道感染和皮肤浅部真菌感染的药物。
所述妇女生殖道感染包含细菌性阴道炎、念珠菌性阴道炎、滴虫性阴道炎、混合性阴道炎、支原体衣原体感染、淋球菌感染、宫颈炎和宫颈糜烂。
所述皮肤浅部真菌感染包含痤疮、粉刺、发癣、须癣、体癣、股癣、手癣、足癣或脚气、黄癣、甲癣、牛皮癣和迭癣。
一种以含银杀菌剂H4Ag2O6为有效成分的防治妇女生殖道感染和皮肤浅部真菌感染的药物。
所述以含银杀菌剂H4Ag2O6为有效成分的防治妇女生殖道感染和皮肤浅部真菌感染的药物组分，包括含银杀菌剂H4Ag2O6和制药学上允许的载体。
所述以含银杀菌剂H4Ag2O6为有效成分的防治妇女生殖道感染和皮肤浅部真菌感染的药物，其凝胶剂药物组方是，浓度3000ppm的H4Ag2O6溶液100ml，聚乙二醇55.690g，卡伯母42.690g，羟基苯甲酸甲酯0.5g，蒸馏水加至组方总量为1000g。
本发明所述的含银杀菌剂H4Ag2O6，是按照中国专利ZL97108681.8公开的制备方法，以氧化银或过氧化银为原料制备而成的，避免了现有技术中常用硝酸银为原料制备含银杀菌剂，溶液中易存在大量硝酸根限制银离子应用的缺点。因此，H4Ag2O6溶液具有银离子浓度高，不含硝酸根，抗菌性能强等优点。以含银杀菌剂H4Ag2O6为有效成分制备的防治妇女生殖道感染和皮肤浅部真菌感染药物，有很强的抗菌性能，具有广阔的应用前景。
具体实施方式
以下通过实施例说明本发明的详细内容。
实施例1：含银杀菌剂H4Ag2O6的制备方法。
按中国专利ZL97108681.8所公开的H4Ag2O6溶液制备方法，包括以下步骤：
(1)取银的氧化物(包括氧化银或过氧化银)10g，加入蒸馏水1000ml；(2)搅拌15～60分钟后，逐滴加入浓硫酸，调整PH值为2～3.5；(3)澄清至少2小时，倒出澄清液；(4)向沉淀物中加入30％的过氧化氢(H2O2)10ml，得到H4Ag2O6溶液。
实施例2、含银杀菌剂H4Ag2O6体外抗菌试验。
体外抗菌试验采用的含银杀菌剂H4Ag2O6浓度为4000mg/L；对照品为成都恩威制药有限公司生产的洁尔阴洗液；试验菌株为：金黄色葡萄球菌ATCC 6538，白色念珠菌ATCC 10231，枯草芽孢杆菌ATCC 6633。试验数据如表1所示。
表1：含银杀菌剂H4Ag2O6体外抗菌试验数据表
| 试验菌株 | 样品浓度mg/L | 不同时间(min)杀菌率(％) | |||
| 1 | 3 | 5 | 10 | ||
| 金黄色葡萄球菌ATCC6538 | 200 | 99.86％ | 99.89％ | 99.97％ | 100％ |
| 100 | 97.9％ | 99.83％ | 99.97％ | 100％ | |
| 50 | 94.5％ | 99.74％ | 99.94％ | 99.94％ | |
| 对照 | 84.7％ | 95.33％ | 96.37％ | 97.18％ | |
| 枯草芽孢杆菌ATCC6633 | 200 | 92.33％ | 92.61％ | 92.94％ | 92.96％ |
| 100 | 90.97％ | 91.43％ | 91.43％ | 91.54％ | |
| 50 | 90.82％ | 91.18％ | 91.32％ | 91.61％ | |
| 对照 | 91.0％ | 91.32％ | 91.36％ | 91.90％ | |
| 白色念珠菌ATCC10231 | 200 | 99.76％ | 99.84％ | 99.84％ | 100％ |
| 100 | 99.27％ | 99.66％ | 99.84％ | 99.92％ | |
| 50 | 95.3％ | 94.73％ | 98.31％ | 96.11％ | |
| 对照 | 76.62％ | 84.0％ | 90.08％ | 93.71 | |
体外杀菌试验结果表明：含银杀菌剂H4Ag2O6对金黄色葡萄球菌具有很强的杀伤作用，三种浓度(50mg/L、100mg/L、200mg/L)下作用5分钟，杀菌率可达到99.9％以上；对枯草芽孢杆菌也有一定的杀伤作用，三种浓度(50mg/L、100mg/L、200mg/L)下，杀菌率可以达到90％以上；对白色念珠菌具有较强的杀伤作用，三种浓度(50mg/L、100mg/L、200mg/L)下作用10分钟，杀菌率平均可以达到98.7％以上。
实施例3：含H4Ag2O6的洗液剂药物的制备。
处方：H4Ag2O6溶液(浓度2000ppm) 100ml
甘油 10ml
丙二醇 8ml
薄荷油 5ml
合计加蒸馏水至 1000ml
按常规方法制备，规格100ml/瓶，浓度2000ppm。
用药方式：直接或稀释10～20倍后冲洗、擦洗使用。用完以纸巾拭干皮肤即可，无需用水清洗。
实施例4：含H4Ag2O6的凝胶剂药物的制备。
处方：H4Ag2O6溶液(浓度3000ppm) 100.000ml
聚乙二醇 55.690g
卡伯母 42.690g
羟基苯甲酸甲酯 0.500g
合计加蒸馏水至 1000.000g
按照凝胶的常规方法制备，再装入特制的给药器中，规格：10g/支或3g/支。
使用方法：每晚睡前，将载有抗菌凝胶剂药物的给药器轻轻插入阴道深部，用推杆将抗菌凝胶剂药物推入即可。每晚1支，3～6天为一疗程。治疗阴道炎：1个疗程，重者酌情增加疗程；治疗宫颈炎：1～2个疗程，重者酌情增加疗程。
实施例5：含H4Ag2O6的泡沫剂药物的制备。
处方：H4Ag2O6(浓度2000ppm) 100ml
甘油 10ml
薄荷油 8ml
土温80 5ml
合计加蒸馏水至 1000ml
制备方法：
(1)取上述配量的H4Ag2O6作为A液。
(2)将上述配量的薄荷油、甘油、土温80混合搅拌均匀，成为B液。
(3)将A、B两液混合并搅拌均匀，再加入蒸馏水至1000ml，搅拌均匀得C液。
(4)将C液罐入耐压容器中并加入抛射剂，制为成品，规格：100ml/瓶。
使用方法：每晚睡前，用一次性导管轻轻插入阴道，按1～2下喷嘴即可。每晚1次，3～6天为一疗程。治疗阴道炎：1个疗程，重者酌情增加疗程；治疗宫颈炎：1～2个疗程，重者酌情增加疗程。
实施例6：含H4Ag2O6的软膏剂药物的制备。
处方：H4Ag2O6溶液(浓度1000ppm) 100ml
白凡士林 800g
橄榄油 100g
合计 1000g
制备方法：将含银杀菌剂H4Ag2O6分散于橄榄油中，搅拌融化了的白凡士林，同时加入含有H4Ag2O6的橄榄油，混匀后灌装，规格10g/支。
使用方法：用手涂抹到真菌感染的部位，每日2～3次。
实施例7：含H4Ag2O6的喷雾剂药物的制备。
利用实施例3所制做的H4Ag2O6的洗液剂药物，装于喷雾装置中，即可成喷雾剂药物，可以用于治疗皮肤真菌感染。
实施例8：含H4Ag2O6的栓剂药物的制备。
处方：H4Ag2O6溶液(浓度4000ppm) 10ml
甘油明胶 85g
甘油 5g
合计 100g
制备方法：将含银杀菌剂H4Ag2O6分散于甘油中，搅拌融化了的甘油明胶，同时加入含银杀菌剂H4Ag2O6的甘油，混匀后灌装，规格：5g/只或3g/只。
使用方法：每晚睡前，将栓轻轻插入阴道深部即可，每晚1只，3～6天为一疗程；治疗阴道炎：1个疗程，重者酌情增加疗程；治疗宫颈炎：1～2个疗程，重者酌情增加疗程。
实施例9、以含银杀菌剂H4Ag2O6为有效成分制备的洗液剂药物用于皮肤浅部真菌感染的防治试验。
以含银杀菌剂H4Ag2O6为有效成分制备的洗液剂作为本试验的药物；选用由中国微生物菌种保藏管理委员会医学真菌中心提供的常见5属12种致病真菌的标准菌株作为试验对象；所用培养基以不含任何抗生素的沙堡氏液体培养基为基础培养基；以液体微量稀释法作为检测方法。实验结果如表2所示。
表2：以H4Ag2O6为有效成分制备的洗液剂药物
体外抗常见5属12种致病真菌的MIC测定结果
| 菌名 | 培养基H4Ag2O6浓度(ppm/ml) | MIC(ppm/ml) | |||||||||
| 350 | 175 | 87.5 | 44 | 22 | 11 | 5.5 | 2.75 | 1.4 | 0.7 | ||
| 红色毛癣菌 | - | - | - | - | - | - | - | + | + | 5.5 | |
| 须癣毛癣菌 | - | - | - | - | - | - | + | + | + | + | 11 |
| 许兰毛癣菌 | - | - | - | - | - | - | + | + | + | + | 11 |
| 紫色毛癣菌 | - | - | - | - | - | - | - | + | + | + | 5.5 |
| 断发毛癣菌 | - | - | - | - | - | - | + | + | + | + | 11 |
| 犬小孢子菌 | - | - | - | - | - | - | + | + | + | + | 11 |
| 石膏样小孢子菌 | - | - | - | - | - | - | + | + | + | + | 11 |
| 絮状表皮癣菌 | - | - | - | - | - | - | - | - | + | + | 2.75 |
| 白色念珠菌 | - | - | - | - | - | - | + | + | + | + | 11 |
| 糠秕马拉色菌 | - | - | - | - | - | + | + | + | + | + | 22 |
| 含轴马拉色菌 | - | - | - | - | + | + | + | + | + | + | 44 |
| 球形马拉色菌 | - | - | - | - | - | + | + | + | + | + | 22 |
注：“+”菌生长，表示无抗菌作用，“-”菌未生长，表示有抑菌作用。
实施例10、以H4Ag2O6为有效成分制备的凝胶剂药物治疗皮肤真菌病的临床试验。
本实施例临床试验采用的凝胶药物含银离子500ppm。皮肤真菌病受试患者共60例，男53例，女7例，其中体股癣35例，病程1周至5年；手足癣25例，病程1周至20年。真菌培养分离出红色毛癣菌25株，其它皮肤癣菌6株。临床试验疗效评价如表3所示。
表3以H4Ag2O6为有效成分制备的凝胶药物
治疗皮肤真菌病的临床及真菌学疗效评价
| 例数 | 治愈 | 显效 | 有效 | 无效 | 有效率 | 真菌清除率 | |
| 体股癣 | 35 | 7(20) | 8(22.9) | 14(40) | 6(17.1) | 82.9％ | 62.9％ |
| 手足癣 | 25 | 4(16) | 6(24) | 7(28) | 8(32) | 68％ | 60.0％ |
| 合计 | 60 | 11(18.3) | 14(23.3) | 21(35) | 14(23.3) | 76.6％ | 61.7％ |
不良反应评价：整个临床试验期间内均无不良反应发生。
Claims (1)
1、一种以含银杀菌剂H4Ag2O6为有效成分的防治妇女生殖道感染和皮肤浅部真菌感染的药物，其凝胶剂药物组方是，浓度3000ppm的H4Ag2O6溶液100ml，聚乙二醇55.690g，卡伯母42.690g，羟基苯甲酸甲酯O.5g，蒸馏水加至组方总量为1000g。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100622951A CN1307881C (zh) | 2004-07-05 | 2004-07-05 | 含银杀菌剂H4Ag2O6的新用途及其制备的药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100622951A CN1307881C (zh) | 2004-07-05 | 2004-07-05 | 含银杀菌剂H4Ag2O6的新用途及其制备的药物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1586498A CN1586498A (zh) | 2005-03-02 |
| CN1307881C true CN1307881C (zh) | 2007-04-04 |
Family
ID=34603681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100622951A Expired - Fee Related CN1307881C (zh) | 2004-07-05 | 2004-07-05 | 含银杀菌剂H4Ag2O6的新用途及其制备的药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1307881C (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101947313B (zh) * | 2010-08-30 | 2012-09-05 | 苏州邦安新材料科技有限公司 | 一种治疗脚气泡腾片及其制备工艺 |
| CN102861102A (zh) * | 2012-09-21 | 2013-01-09 | 华绣科技有限公司 | 一种纳米银抑菌喷剂 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1214867A (zh) * | 1997-10-21 | 1999-04-28 | 蒋华德 | 含银杀菌剂的制备方法 |
| CN1480584A (zh) * | 2002-09-06 | 2004-03-10 | 刘维春 | 利用纳米银与活性碳纤维的结合制作抗菌材料的方法 |
-
2004
- 2004-07-05 CN CNB2004100622951A patent/CN1307881C/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1214867A (zh) * | 1997-10-21 | 1999-04-28 | 蒋华德 | 含银杀菌剂的制备方法 |
| CN1480584A (zh) * | 2002-09-06 | 2004-03-10 | 刘维春 | 利用纳米银与活性碳纤维的结合制作抗菌材料的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1586498A (zh) | 2005-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102387793B (zh) | 包括银离子源和薄荷醇的抗菌组合物及其用途 | |
| CN102499944B (zh) | 一种纳米银抗菌抗病毒组合液及其制备方法和产物 | |
| CN1649603A (zh) | 包含甲硝唑的含水组合物 | |
| CN1899291A (zh) | 外用抗真菌的复方组合物及其应用 | |
| Xu et al. | Antifungal nanomaterials: current progress and future directions | |
| Hu et al. | Studies on antimicrobial peptide-loaded nanomaterial for root caries restorations to inhibit periodontitis related pathogens in periodontitis care | |
| CN102293771A (zh) | 一种治疗浅部真菌感染的药物组合物及其应用 | |
| CN1307881C (zh) | 含银杀菌剂H4Ag2O6的新用途及其制备的药物 | |
| CN112022902A (zh) | 一种碳点改性氟康唑桉叶油微乳凝胶制备方法及应用 | |
| CN1927181A (zh) | 一种特比萘芬纳米乳抗真菌药物及其制备方法 | |
| CN1251738C (zh) | 一种治疗灰指甲的中药及其制备方法 | |
| EP1374903B1 (en) | Pharmaceutical composition for the prevention of the development and progression of mycotic skin surface diseases | |
| CN1369206A (zh) | 钠米银消毒凝胶及其制备方法和应用 | |
| CN1672689A (zh) | 治疗妇女生殖道感染的纳米银抗菌凝胶，制备方法及应用 | |
| CN1943593A (zh) | 妇科外用抗菌泡沫剂 | |
| CN1857309A (zh) | 妇女用纳米银喷剂及其制备方法 | |
| CN1264508C (zh) | 治疗妇科疾病的青蒿素制剂 | |
| CN1259919C (zh) | 一种杀菌、抑菌药物组合物及其制剂和制备工艺 | |
| CN109876007B (zh) | 一种臭氧抗菌灭毒凝胶及其制备方法 | |
| CN100344310C (zh) | 含有生物碱盐的治癣药物及其制备工艺 | |
| CN1583165A (zh) | 林蛙抗菌肽凝胶剂及其制备方法 | |
| CN105434431B (zh) | 一种多功能外用抗菌制剂及其制备方法和应用 | |
| CN1583166A (zh) | 林蛙抗菌肽喷雾剂及其制备方法 | |
| CN114272240B (zh) | 抗感染复方制剂及其应用 | |
| CN1063632C (zh) | 一种治疗皮肤病的外用搽剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: SHENZHEN CITY YUANXING BIOLOGY PHARMACEUTICAL TECH Free format text: FORMER NAME OR ADDRESS: TSINGHUA YUANXING BIO-PHARM TECHNOLOGY CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 518057 Shenzhen City, north of Nanshan District high tech Development Zone Lang Shan Lu Qinghua Yuanxing pharmaceutical company hospital Patentee after: Shenzhen Yuanxing Bio-Pharm Co., Ltd. Address before: 100010, F, room 8, building 12, Huan Tai tower, Zhongguancun South Road, Haidian District, Beijing Patentee before: Tsinghua Yuanxing Biomedicine Tech Co., Ltd., Shenzhen |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Shenzhen Yuanxing Nano-Pharmaceutical Co., Ltd. Assignor: Shenzhen Yuanxing Bio-Pharm Co., Ltd. Contract record no.: 2010440020102 Denomination of invention: New use of silver containing bactericide H*Ag*O* and preparation thereof Granted publication date: 20070404 License type: Exclusive License Open date: 20050302 Record date: 20100706 |
|
| ASS | Succession or assignment of patent right |
Owner name: SHENZHEN YUANXING NANO-PHARMA CO.,LTD. Free format text: FORMER OWNER: SHENZHEN YUANXING BIO-PHARM CO., LTD. Effective date: 20150909 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150909 Address after: 518000 Guangdong city of Shenzhen province Nanshan District high tech Industrial Park, North Central Avenue, North Song Ping Road No. 1 Lite technology building south 10 layer 1001 Patentee after: Shenzhen Yuanxing Nano-Pharmaceutical Co., Ltd. Address before: 518057 Shenzhen City, north of Nanshan District high tech Development Zone Lang Shan Lu Qinghua Yuanxing pharmaceutical company hospital Patentee before: Shenzhen Yuanxing Bio-Pharm Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070404 Termination date: 20160705 |